Funding Support and Author Disclosures The PIONEER-HF and PARAGLIDE-HF trials were supported by Novartis Pharmaceuticals Corp. Drs Morrow and Park are members of the TIMI Study Group, which has received institutional research grant support through Brigham and Women’s Hospital from Abbott, Abiomed, Amgen, Anthos Therapeutics, ARCA Biopharma, AstraZeneca, Bayer HealthCare Pharmaceuticals, Daiichi-Sankyo, Eisai, Intarcia, Ionis Pharmaceuticals, Janssen Research and Development, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Roche, Siemens Healthcare Diagnostics, Softcell Medical Limited, and Zora Biosciences. Dr Morrow has received consulting fees from Abbott Laboratories, ARCA Biopharma, Inflammatix, Merck and Co, Novartis, Regeneron, and Roche Diagnostics. Dr Velazquez has received institutional research grant support and/or honoraria for serving on advisory boards from Novartis, Abiomed, Rednvia, and the National Heart, Lung, and Blood Institute/National Institutes of Health. Dr Desai has received research grants (to Brigham and Women’s Hospital) from Abbott, Alnylam, AstraZeneca, Bayer, and Novartis; and has received personal consulting fees from Abbott, Alnylam, AstraZeneca, Avidity Biopharma, Axon Therapeutics, Bayer, Biofourmis, Cytokinetics, GlaxoSmithKline, Medpace, Merck, New Amsterdam, Novartis, Parexel, Regeneron, River2Renal, Roche, Verily, and Veristat. Dr DeVore has received research funding through his institution from Biofourmis, Bodyport, Cytokinetics, American Regent, Inc, the National Institutes of Health and National Heart, Lung, and Blood Institute, Novartis, and Story Health; and has served as a consultant for and/or received honoraria from Abiomed, Cardionomic, LivaNova, Natera, Novo Nordisk, Story Health, and Zoll. Dr Sharma has served on the advisory board and/or as a consultant for Alleviant, AstraZeneca, Bayer, Boehringer Ingelheim, Edwards Lifesciences, Imbria, Novartis, Novo Nordisk, RIVUS, and ViCardia. Dr Solomon has received research grants from Alnylam, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Cytokinetics, Eidos, GlaxoSmithKline, Ionis, Lilly, MyoKardia, National Institutes of Health/National Heart, Lung, and Blood Institute, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Theracos, Actelion, Amgen, Bellerophon, Celladon, Gilead, Mesoblast, Neurotronik, and US2; and has served as a consultant for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, MyoKardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Valo. Dr Starling has served on the steering committee for the PARAGLIDE trial sponsored by Novartis and for the RESPONDER HF trial sponsored by Corvia Medical. Drs Ward and Williamson are employees of Novartis. Dr Zieroth has received research grant support from, served on advisory boards for, or served as a speaker for Abbott, Akcea AstraZeneca, Amgen, Alnylam, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Servier, and Vifor Pharma; and has served on a clinical trial committee or as a national lead for studies sponsored by AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, and Pfizer. Dr Hernandez has received research grants from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Merck, Novartis, Novo Nordisk, Somologic, and Verily; and has served as a consultant for Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Intellia, Merck, Novartis, and Novo Nordisk. Dr Mentz has received research support and/or honoraria from Novartis, Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Eli Lilly, Medtronic, Medable, Merck, Novo Nordisk, Pharmacosmos, Relypsa, Respicardia, Roche, Sanofi, Vifor, Windtree Therapeutics, and Zoll. Dr Braunwald has received grant support to his institution from Novartis for the conduct of the PIONEER-HF trial, for serving on the Executive Committee of the PARADISE-MI trial and the Steering Committee of the PARAGLIDE-HF trial, and for participation in an advisory board meeting; and has served as a consultant for Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Cardurion, Edgewise, and Verve. Dr Lepage has reported that he has no relationships relevant to the contents of this paper to disclose.